


Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults.

Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829, 861, 918, 920 & local agreements



Version	3.0
Developed by	Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
Approved by	Hertfordshire & West Essex Area Prescribing Committee
Date approved / updated	November 2023
Review Date	This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
Superseded versions	<p>Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829 & local agreements. Version 1.0. HWE APC, February 2023</p> <p>Pathway for use of biologic drugs for Axial Spondyloarthritis West Essex CCG MOPB, October 2021</p> <p>Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829 & local agreements v1.0 February 2023</p> <p>Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829, 861 & local agreements v 2.0 March 2023 (bimekizumab & tofacitinib added)</p>